TLDR
- Novo Nordisk and Hims & Hers plan to announce a new partnership as soon as Monday to sell obesity drugs together
- Hims stock surged 39% in after-hours trading on the news
- The deal ends a legal dispute, including a patent infringement lawsuit filed by Novo last month
- Novo previously terminated an earlier agreement with Hims over marketing tactics and compounded drug sales
- The FDA had also threatened action against Hims over its $49 compounded semaglutide copy
Novo Nordisk and Hims & Hers plan to sell obesity drugs together through Hims’ telehealth platform, ending a legal feud that had escalated into a patent lawsuit just weeks ago.
JUST IN:
Novo Nordisk $NVO plans to sell its weight-loss drugs on Hims & Hers Health's $HIMS platform – Bloomberg pic.twitter.com/iVCqiusEyY
— Evan (@StockMKTNewz) March 7, 2026
Bloomberg News first reported the deal on Friday, citing a person familiar with the matter. Hims stock jumped 39% in after-hours trading following the report.
The two companies are expected to make a formal announcement as soon as Monday. Financial terms of the arrangement were not disclosed.
From Lawsuit to Partnership
The turnaround is striking. Just last month, Novo filed a patent infringement lawsuit against Hims after the telehealth company launched — and then pulled — a $49 compounded version of Novo’s obesity pill.
The U.S. Food and Drug Administration had also warned it could take action against Hims over the sale of compounded semaglutide, the active ingredient in Wegovy and Ozempic.
That regulatory pressure, combined with the legal challenge from Novo, put Hims in a difficult spot heading into this week.
This isn’t the first time the two companies have tried to work together. Novo ended a previous agreement with Hims last year, citing concerns over Hims’ marketing tactics and its continued sale of copycat Wegovy products.
The new deal represents a second attempt at collaboration, this time apparently on terms both sides can agree to.
What the Deal Means for Both Companies
For Novo, the partnership offers another distribution channel for its branded weight-loss drugs at a time when competition in the obesity drug market is heating up.
A Novo spokesperson said the company is “always in conversation with companies that can help improve patient access to FDA-approved medicines.” That’s about as much as Novo has said publicly.
Hims did not respond to a request for comment ahead of publication.
For Hims, the deal is a clear pivot. The company had been leaning into compounded semaglutide as a low-cost alternative to Novo’s drugs.
That strategy ran into a wall when the FDA declared semaglutide no longer in shortage earlier this year, effectively cutting off the legal basis for compounding pharmacies to keep making it.
Where Things Stand
Hims stock was up 39% in after-hours trading Friday. During regular trading, both NVO and HIMS were in the red — NVO down 1.25% and HIMS down 0.88%.
The formal announcement is expected as soon as Monday, March 9.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
